Join the club for FREE to access the whole archive and other member benefits.

$72m funding launching Pretzel Therapeutics pioneering mitochondrial therapies

12-Sep-2022

Key points from article :

Pretzel Therapeutics launched with $72.5 million in Series A financing.

Will develop novel, mitochondria-based therapies for rare genetic disorders and diseases of aging. 

Plans to target mitochondrial diseases, a highly heterogenous group of conditions caused by DNA mutations.

Pretzel’s approach to mitochondrial pathology has three paths:

  •  genome correction (to silence faulty copies of mitochondrial DNA)
  •  modulating gene expression (targeting enzymes and other cofactors involved)
  •  modulating the innate quality control system of mitochondria

ARCH Venture Partners and Mubadala Capital led the Series A financing. 

"In the 5-10-year horizon, ... all three of our platform approaches – genome correction, genome expression modulation and mitochondrial quality control – across a variety of different indications," CEO Jay Parrish said.

 "It’s likely that that first clinical program will be in the area of mitochondrial rare diseases," Parrish added. 

Pretzel targets genome correction, genome expression modulation and mitochondrial quality control

Mentioned in this article:

Click on resource name for more details.

Jay Parrish

Chairman and Chief Executive Officer at Pretzel Therapeutics

Pretzel Therapeutics

Biotechnology research company focussed on mitochondrial therapeutics